HIGHLIGHTS
- who: Quentin Delbaere and colleagues from the Department of Cardiology, Arnaud de Villeneuve University Hospital, Montpellier, France have published the research: Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases, in the Journal: Pharmaceuticals 2023, 16, 78. of /2023/
- what: The inflammatory pathway of atherosclerosis is an emerging therapeutic target in drug development.
- how: The P-selectin inhibitor inclacumab was tested in a randomized trial of 544 patients with MI without ST-elevation (NSTEMI) the authors showed a non-significant trend in troponin reduction compared to placebo . The anti-IL-6 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.